Biomarker · Gene alteration

TP53 mutation

Somatic TP53 mutations detected by sequencing of tumor tissue or marrow; used mainly as a prognostic and risk-stratification marker across solid and hematologic malignancies.

CI-BIO-00000034TP53 graph →NCIt C118396

Also calledTP53-mutated · p53 mutation · TP53-mutant

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Neoplasm	21	21	—	—	0 / 1 / 0 / 19 / 1
Malignant Breast Neoplasm	15	5	10	—	0 / 11 / 1 / 2 / 1
Chronic Lymphocytic Leukemia	7	1	6	—	1 / 6 / 0 / 0 / 0
Malignant Ovarian Neoplasm	7	4	3	—	0 / 5 / 2 / 0 / 0
Gastric Carcinoma

Derived

Drugs with predictive evidence (24)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
MDM2 Inhibitor AMGMDS3	17	1	16	D	1 / 16	Malignant Neoplasm
CisplatinSmall Molecule	9	4	5	B	3 / 5	Gastric Carcinoma, Malignant Gastric Neoplasm,

Curated evidence

Predictive evidence items (52)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 52 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 Mutation8
Alemtuzumab

Regulatory

Approvals mentioning the linked drugs (444)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpd

Clinical trials

Active trials (1,111)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 558 recruiting · 287 active phase 3 · 5,094 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 201–250 of 1,111 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07283939	Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays	recruiting	N/A	420	Alliance for Clinical Trials in Oncology

Literature

Linked publications (58)

Publications linked to the scope gene(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 58 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411

TP53 Wildtype6
Chemotherapy	Esophageal Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID906 Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC) PMID 23515910 · Zhang et al., 2013 · Open in CIViC	civic
RG7112	Leukemia	Predictive	B	Supports Sensitivity Response	3	accepted	EID2965 Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild … (full text at CIViC) PMID 26459177 · Andreeff et al., 2016 · Open in CIViC	civic
Adjuvant Chemotherapy	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1149 Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) vers… (full text at CIViC) PMID 26899019 · Ma et al., 2016 · Open in CIViC	civic
Capecitabine + Cetuximab + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID875 In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; h… (full text at CIViC) PMID 24957073 · Sclafani et al., 2014 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID2964 MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor. PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Rebemadlin	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID2963 MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional T… (full text at CIViC) PMID 17671205 · Efeyan et al., 2007 · Open in CIViC	civic

TP53 R273C2
Cisplatin + Etoposide + MitomycinCombination	Gastric CarcinomaALIAS	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID2292 A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID4881 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 Y220C2
Cisplatin + Etoposide + MitomycinCombination	Gastric CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID2306 A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric … (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID4884 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 R175H4
EAP Protocol	Gastric CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	—	accepted	EID2310 In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment o… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
Doxorubicin	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID319 Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53. PMID 22698404 · Jackson et al., 2012 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID4880 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID10074 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 Deleterious Mutation4
RG7112	Leukemia	Predictive	B	Supports Resistance	3	accepted	EID2966 Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type… (full text at CIViC) PMID 26459177 · Andreeff et al., 2016 · Open in CIViC	civic
Adjuvant Chemotherapy	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID1148 Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt … (full text at CIViC) PMID 26899019 · Ma et al., 2016 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID2967 MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while th… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Rebemadlin	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID2968 MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking … (full text at CIViC) PMID 17671205 · Efeyan et al., 2007 · Open in CIViC	civic

TP53 Overexpression2
Cisplatin + Etoposide + MitomycinCombination	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID2799 In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater t… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	3	accepted	EID3013 In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/r… (full text at CIViC) PMID 11595686 · Reles et al., 2001 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Etoposide	CA Health Canada	—	Marketed in Canada as VEPESID (DIN 00616192) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1984	health-canada-dpd
Etoposide	CA Health Canada	—	Marketed in Canada as VEPESID INJ 20MG/ML (DIN 00523410) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 30, 2007	Dec 31, 1981	health-canada-dpd
Etoposide	CA Health Canada	—	Marketed in Canada as PMS-ETOPOSIDE (DIN 02237871) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017	—	health-canada-dpd
Etoposide	CA Health Canada	—	Marketed in Canada as EPOSIN (DIN 02237428) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 1, 2017	—	health-canada-dpd
Etoposide	CA Health Canada	—	Marketed in Canada as DOM-ETOPOSIDE (DIN 02237872) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 3, 2017	—	health-canada-dpd
Etoposide	CA Health Canada	—	Marketed in Canada as ETOPOSIDE (DIN 02237873) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Sep 12, 2017	—	health-canada-dpd
Etoposide	US FDA	Malignant Testicular Neoplasm	Refractory testicular cancer	approved	Feb 13, 2026	openfda
Etoposide	US FDA	Lung Small Cell Carcinoma	Small cell lung cancer	approved	Feb 13, 2026	openfda
Etoposide	US FDA	—	Refractory testicular tumors, in combination with other chemotherapeutic drugs.	approved	May 17, 1996	openfda
Etoposide	US FDA	Lung Small Cell Carcinoma	Small cell lung cancer, in combination with cisplatin, as first-line treatment.	approved	May 17, 1996	openfda
Etoposide	US FDA	Lung Small Cell Carcinoma	VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer— VePesid Capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.	approved	Dec 30, 1986	openfda
Idelalisib	EU EMA	—	Zydelig is indicated in combination with an anti?CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.	approved	Sep 18, 2014	ema
Methotrexate	CA Health Canada	—	Marketed in Canada as PMS-METHOTREXATE TABLETS (DIN 02561956) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 28, 2025	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as JAMP METHOTREXATE TABLETS (DIN 02553740) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 10, 2025	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as M-METHOTREXATE (DIN 02534916) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 24, 2024	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as ACH-METHOTREXATE (DIN 02509067) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 21, 2021	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02464365) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 22, 2020	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02474735) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 23, 2019	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02474891) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 23, 2019	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION, USP (DIN 02417626) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 4, 2024	Aug 14, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422182) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422174) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422190) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422166) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION, BP (DIN 02422204) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 8, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as JAMP-METHOTREXATE (DIN 02419173) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Nov 14, 2022	Mar 12, 2014	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02398427) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 28, 2023	Feb 14, 2013	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02327236) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2011	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METOJECT (DIN 02320053) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 19, 2017	Jan 26, 2009	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METOJECT (DIN 02320045) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 17, 2019	Jan 26, 2009	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METOJECT (DIN 02320029) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jun 29, 2022	Jan 26, 2009	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METOJECT (DIN 02320037) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 23, 2020	Jan 26, 2009	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METOJECT (DIN 02304767) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 19, 2017	May 30, 2008	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE TABLETS, USP (DIN 02182750) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 12, 2004	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as RATIO-METHOTREXATE SODIUM (DIN 02244798) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 7, 2018	Nov 14, 2001	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as APO-METHOTREXATE (DIN 02182963) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 17, 1999	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02182955) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 13, 1998	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02182777) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 30, 1998	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02182971) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 30, 1997	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02182947) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 30, 1997	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE-LIQ IM IV IAR INT IVR 25MG/ML (DIN 02170663) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 19, 2001	Feb 4, 1997	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE-PWS IM IV IAR INT IVR 20MG/VIAL (DIN 02170655) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 22, 2001	Feb 4, 1997	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE (DIN 02170671) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 3, 2011	Jan 24, 1997	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as PMS-METHOTREXATE (DIN 02170698) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 15, 1996	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE SODIUM INJECTION USP (DIN 02161168) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 2, 2006	Sep 5, 1996	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE SODIUM INJECTION (DIN 02099705) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1995	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE SODIUM INJ 25MG/ML USP (DIN 01911457) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 10, 1999	Dec 31, 1992	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE TAB 2.5MG USP (DIN 00632619) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 1, 2000	Dec 31, 1991	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as METHOTREXATE SOD INJ 25MG/ML USP (DIN 02084481) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1990	health-canada-dpd
Methotrexate	CA Health Canada	—	Marketed in Canada as RHEUMATREX TAB 2.5MG (DIN 00874132) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 2, 2000	Dec 31, 1990	health-canada-dpd